Plus therapeutics reports first quarter financial results and recent business highlights

Company continues to progress both reyobiq™ radiotherapeutic clinical trials and cnside® csf assay platform launch readiness houston, may 30, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces financial results for the first quarter ended march 31, 2025, and provides an overview of recent and upcoming business highlights. “we improved our cash position in the first quarter as a result of both a financing and grant support,” said marc h.
PSTV Ratings Summary
PSTV Quant Ranking